Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Cost-effectiveness analysis of early versus late total hip replacement in Italy.

Mota RE.

Value Health. 2013 Mar-Apr;16(2):267-79. doi: 10.1016/j.jval.2012.10.020. Epub 2013 Jan 26. Review.

2.

Cost analysis and sociomedical aspects of the conservative and surgical treatment of hip osteoarthritis.

Dutka J, Dutka L, Janiszewski M, Hajduk G.

Ortop Traumatol Rehabil. 2008 Nov-Dec;10(6):537-46. English, Polish.

PMID:
19153542
3.

Cost-utility of metal-on-metal hip resurfacing compared to conventional total hip replacement in young active patients with osteoarthritis.

Heintzbergen S, Kulin NA, Ijzerman MJ, Steuten LM, Werle J, Khong H, Marshall DA.

Value Health. 2013 Sep-Oct;16(6):942-52. doi: 10.1016/j.jval.2013.06.021.

4.

Cost of joint replacement surgery for osteoarthritis: the patients' perspective.

March L, Cross M, Tribe K, Lapsley H, Courtenay B, Brooks P.

J Rheumatol. 2002 May;29(5):1006-14.

PMID:
12022316
5.

A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip.

Chang RW, Pellisier JM, Hazen GB.

JAMA. 1996 Mar 20;275(11):858-65.

PMID:
8596224
6.

Socioeconomic burden of total joint arthroplasty for symptomatic hip and knee osteoarthritis in the Italian population: a 5-year analysis based on hospitalization records.

Piscitelli P, Iolascon G, Di Tanna G, Bizzi E, Chitano G, Argentiero A, Neglia C, Giolli L, Distante A, Gimigliano R, Brandi ML, Migliore A.

Arthritis Care Res (Hoboken). 2012 Sep;64(9):1320-7. doi: 10.1002/acr.21706.

7.

Randomised controlled trial of the cost-effectiveness of water-based therapy for lower limb osteoarthritis.

Cochrane T, Davey RC, Matthes Edwards SM.

Health Technol Assess. 2005 Aug;9(31):iii-iv, ix-xi, 1-114.

8.

Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.

Haentjens P, De Groote K, Annemans L.

Arch Orthop Trauma Surg. 2004 Oct;124(8):507-17. Epub 2004 Sep 10.

PMID:
15365714
9.
10.

Cost-effectiveness of nonpharmacologic, nonsurgical interventions for hip and/or knee osteoarthritis: systematic review.

Pinto D, Robertson MC, Hansen P, Abbott JH.

Value Health. 2012 Jan;15(1):1-12. doi: 10.1016/j.jval.2011.09.003. Epub 2011 Nov 29. Review.

11.

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

Pharmacoeconomics. 2012 Feb 1;30(2):87-101. doi: 10.2165/11599370-000000000-00000.

PMID:
22187932
12.

Predicting the cost-effectiveness of total hip and knee replacement: a health economic analysis.

Jenkins PJ, Clement ND, Hamilton DF, Gaston P, Patton JT, Howie CR.

Bone Joint J. 2013 Jan;95-B(1):115-21. doi: 10.1302/0301-620X.95B1.29835.

PMID:
23307684
14.

Quality of life and cost-effectiveness 1 year after total hip arthroplasty.

Lavernia CJ, Alcerro JC.

J Arthroplasty. 2011 Aug;26(5):705-9. doi: 10.1016/j.arth.2010.07.026. Epub 2010 Sep 25.

PMID:
20870386
15.

Determinants of willingness to pay for hip and knee joint replacement surgery for osteoarthritis.

Cross MJ, March LM, Lapsley HM, Tribe KL, Brnabic AJ, Courtenay BG, Brooks PM.

Rheumatology (Oxford). 2000 Nov;39(11):1242-8.

PMID:
11085804
16.

Cost-effectiveness of antibiotic-impregnated bone cement used in primary total hip arthroplasty.

Cummins JS, Tomek IM, Kantor SR, Furnes O, Engesaeter LB, Finlayson SR.

J Bone Joint Surg Am. 2009 Mar 1;91(3):634-41. doi: 10.2106/JBJS.G.01029.

PMID:
19255224
17.

The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.

Pradelli L, Iannazzo S, Zaniolo O.

Am J Cardiovasc Drugs. 2009;9(6):383-92. doi: 10.2165/11315730-000000000-00000.

PMID:
19929036
18.

Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.

Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, Krukowski Z, Vale L, Grant A.

Health Technol Assess. 2006 Nov;10(45):1-141, iii-iv. Review.

19.

Patterns of pharmacotherapy and health care utilization and costs prior to total hip or total knee replacement in patients with osteoarthritis.

Berger A, Bozic K, Stacey B, Edelsberg J, Sadosky A, Oster G.

Arthritis Rheum. 2011 Aug;63(8):2268-75. doi: 10.1002/art.30417.

20.

Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs.

Räsänen P, Paavolainen P, Sintonen H, Koivisto AM, Blom M, Ryynänen OP, Roine RP.

Acta Orthop. 2007 Feb;78(1):108-15.

PMID:
17453401

Supplemental Content

Support Center